Exploring the causes of death among patients with metastatic prostate cancer - A changing landscape by Merriel, SWD et al.
Invited Commentary | Oncology
Exploring the Causes of Death Among Patients With Metastatic Prostate Cancer—
A Changing Landscape
Samuel W. D. Merriel, MSc; Tanimola Martins, PhD; Sarah E. R. Bailey, PhD
Using data from the Surveillance, Epidemiology, and End Results program, Elmehrath and colleagues1
undertook a large retrospective cohort study of 26 168 patients with metastatic prostate cancer to
determine the common causes of death in this population. Patients were followed up from the date
of diagnosis to death or the end of the study period in 2016, and standardized mortality ratios were
calculated (SMRs) for each cause of death. Most deaths occurred within 2 years of diagnosis (9869 of
16 732 deaths [59.0%]). Black patients had a higher risk of excess death overall compared with White
patients (SMR, 6.68 [95% CI, 6.45-6.91] vs 5.66 [95% CI, 5.57-5.76]). Of all deaths in the cohort,
13 011 (77.8%) were due to prostate cancer, with 924 (5.5%) due to other cancers and 2797 (16.7%)
due to noncancer causes. Cardiovascular disease (SMR, 1.34; 95% CI, 1.26-1.42), cerebrovascular
disease (SMR, 1.31; 95% CI, 1.13-1.50), and chronic obstructive pulmonary disease (SMR, 1.19; 95% CI,
1.03-1.36) were the most common noncancer causes of death, and noncancer deaths were more
common among older patients and patients with longer latency periods from diagnosis to death.
Recognizing the limitations inherent to SMR estimates, this study1 is important considering that
most patients with prostate cancer survive their disease for several years after diagnosis. As such,
identifying the causes of deaths among these patients may help with multidisciplinary treatment
planning. Elmehrath et al1 postulate that hormone therapy treatments may increase the risk of
cardiovascular and cerebrovascular disease in patients treated for metastatic prostate cancer, a
theory that is supported by some epidemiological and biomedical evidence. Their finding of
increased suicide rates among Asian or Pacific Islander patients and White patients with metastatic
prostate cancer is a surprise and should be investigated further, considering that such deaths are
potentially preventable.
Prostate cancer incidence in the US and other Western countries has increased significantly in
recent decades, largely as a result of the widespread use of prostate-specific antigen (PSA) testing.2
However, the incidence rates in countries like the US are stabilizing2 following national
recommendations to reduce PSA testing.3 Mortality from prostate cancer over the same period has
decreased,4 which is thought to be associated with a combination of PSA testing detecting some
cases of prostate cancer earlier, resulting in a lower incidence of metastatic disease at diagnosis, and
greater availability of more-effective treatments for advanced disease.2 Systemic therapies for
prostate cancer, such as hormone therapy and chemotherapy, are not without their adverse effects,
including increased risk of cardiovascular disease and other cancers, as highlighted by Elmehrath
and colleagues.1 This is particularly relevant for prostate cancer, which has a high long-term survival
rate compared with almost all other cancer types,4 and signals the need for greater holistic care for
patients receiving these treatments.
Prostate cancer is expected to remain the most common cancer diagnosed in male individuals
in high-income countries in the next decade, with incidence in low-income and middle-income
countries projected to increase much more rapidly in comparison.5 As observed in this study,1 most
patients with metastatic prostate cancer die from it, rather than other possible causes of death,
reinforcing the need for innovations to promote early-stage diagnosis. The recent development and
implementation of new tests for prostate cancer detection may reduce the proportion of patients
who receive a diagnosis at a late stage, although some metastatic disease at the time of diagnosis will
likely still occur. Multiparametric magnetic resonance imaging (mpMRI) of the prostate before biopsy
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is one such test and has been shown to increase the detection of clinically significant prostate cancer
compared with transrectal ultrasound–guided biopsy. mpMRI can also be used to guide prostate
biopsy to reduce the risk of missed diagnoses that occur with transrectal ultrasound–guided biopsy
biopsy.6 PSA testing is known to be falsely normal in some men with aggressive and/or metastatic
disease,2 so the wider use of mpMRI may detect more clinically significant cancers earlier and help to
reduce the burden of advanced prostate cancer in the future.
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